GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS (2020-2027) - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS (2020-2027)

Description:

Read here the market research report on the “China Osteoporosis Drugs Market" published by CMI Team – PowerPoint PPT presentation

Number of Views:4
Date added: 3 November 2020
Slides: 21
Provided by: kunalbhuta
Category: Other

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS (2020-2027)


1
  • Coherent Market Insights
  • Market Research and Business Consulting Services
  • https//www.coherentmarketinsights.com/
  • COVID-19 Impact Tracker

2
GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET
ANALYSIS (2020-2027)
  • Global and China Osteoporosis Drugs Market, By
    Drug Type (Bisphosphonates (Alendronate,
    Risedronate, Ibandronate, Zoledronic Acid,
    Others), Calcitonin, Hormone Therapy, Selective
    Estrogen Receptor Modulators (SERMs), Parathyroid
    Hormone-Related Protein (PTHrP) Analog, Rank
    Ligand (RANKL) Inhibitor), By Route of
    Administration (Oral, Injectable, Others), By
    Distribution Channel (Hospitals Pharmacies,
    Online Pharmacies, Retail Pharmacies), and By
    Region (North America, Latin America, Europe,
    Asia Pacific, China, Middle East Africa) -
    Size, Share, Outlook, and Opportunity Analysis,
    2020 - 2027

3
  • Osteoporosis is characterized by
    micro-architectural deterioration of bone tissue
    leading to low bone mass and bone fragility,
    especially in the older age. The condition
    affects both sexes however women are more prone
    to it, especially post-menopause when bone loss
    is accelerated due to reduced estrogen, which
    helps protect the bones.

4
Statistics
  • The global and China osteoporosis drugs market is
    estimated to account for US 17.1 Bn in terms of
    value by the end of 2027.

5
Global and China Osteoporosis Drugs Market
Drivers
  • Increasing prevalence of osteoporosis is expected
    to propel growth of the global and China
    osteoporosis drugs market over the forecast
    period. For instance, according to the study,
    The Prevalence of Osteoporosis in China, a
    Nationwide, Multicenter DXA Survey, published in
    October 2019, in The Journal of Bone and Mineral
    Research, the age-standardized prevalence of
    osteoporosis at the spine or hip was 6.46 and
    29.13 for men and women aged 50 years and older,
    respectively. A total of 10.9 million men and
    49.3 million women in China were estimated to
    have osteoporosis.
  • Moreover, increasing geriatric population is also
    expected to aid in growth of the market. For
    instance, according to the United Nations,
    Department of Economic and Social Affairs,
    Population Division, the geriatric population in
    China is expected to reach 246,986 thousands in
    2030 from 164,487 thousands in 2019.

6
Statistics
  • North America held dominant position in the
    global and China osteoporosis drugs market in
    2019, accounting for 38.5 share in terms of
    value, followed by Europe and Asia Pacific,
    respectively.

7
Figure 1 Global and China Osteoporosis Drugs
Market Share () Value, By Region, 2019
8
Global and China Osteoporosis Drugs Market
Restraints
  • Adverse effects of osteoporosis drugs are
    expected to hinder growth of the market. For
    instance, consumption of alendronate may lead to
    stomach pain, acid reflux, constipation,
    diarrhea, upset stomach, nausea, or muscle and
    joint pain.
  • Moreover, low awareness and diagnosis of
    osteoporosis, especially in emerging economies is
    also expected to limit the market growth.

9
(No Transcript)
10
Global and China Osteoporosis Drugs Market
Opportunities 
  • RD in novel therapeutics is expected to offer
    lucrative growth opportunities for players in the
    global and China osteoporosis drugs market. For
    instance, in June 2020, researchers from School
    of Medicine CHA University, South Korea, reported
    that Tauroursodeoxycholic acid, the U.S.
    FDA-approved hydrophilic bile acid for the
    treatment of chronic cholestatic liver disease,
    may provide a favorable effect on bones and could
    be used for the prevention and treatment of
    osteoporosis.
  • Moreover, increasing number of smokers is also
    expected to aid in growth of the market. For
    instance, according to the World Health
    Organization, 1.337 billion people smoked tobacco
    worldwide in 2018.

11
Statistics
  • The global and China osteoporosis drugs market
    was valued at US 12.7 Bn in 2019 and is forecast
    to reach a value of US 17.1 Bn by 2027 at a CAGR
    of 3.8 between 2020 and 2027.

12
  • Figure 2 Global and China Osteoporosis Drugs
    Market Value (US Bn), 2016 2027

13
Market Trends/Key Takeaways
  • Major organizations are focused on reducing the
    burden of osteoporosis. For instance, in June
    2020, The International Osteoporosis Foundation
    partnered with Amgen and UCB, a global
    biopharmaceutical company, in collaboration with
    the University of Oxford, to support its Capture
    the Fracture program, which aims to reduce hip
    and vertebral fractures by 25 by 2025.

14
  • Approval and launch of AI-based products to
    predict osteoporosis is expected to aid in growth
    of the market. For instance, in May 2020, Zebra
    Medical Vision received FDA 510(k) clearance for
    its Vertebral Compression Fractures product,
    which automatically identifies findings
    suggestive of compression fractures, which
    enables clinicians to place patients that are at
    risk of osteoporosis in treatment pathways.

15
Global and China Osteoporosis Drugs Market
Competitive Landscape
  • Major players operating in the global and China
    osteoporosis drugs market include, Merck Co.,
    Eli Lilly, Procter Gamble, Enzo Biochem, Inc.,
    Sanofi-Aventis, Novartis, Wyeth, Roche,
    GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd.,
    Bone Biologics, Teijin Pharma Limited, JHL
    Biotech Inc., Keros Therapeutics, and Taro
    Pharmaceuticals Inc.

16
Global and China Osteoporosis Drugs Market Key
Developments
  • Major players in the market are focused on
    approval and launch of new products to expand
    their product portfolio. For instance, in May
    2020, Teijin Pharma Limited, a partner of Radius
    Health, Inc., submitted a New Drug Application
    for abaloparatide-SC in Japan for the treatment
    of osteoporosis in patients who are at high risk
    for fractures.
  • Similarly, in April 2019, Amgen and UCB received
    the U.S. Food and Drug Administration approval
    for EVENITY (romosozumab-aqqg) for the treatment
    of osteoporosis in postmenopausal women at high
    risk for fracture.

17
  • Request Sample Report
  • Request Customization
  • Download PDF Brochure
  • Talk to Analyst
  • Buy Now
  • Reference https//www.coherentmarketinsights.com/
    market-insight/global-and-china-osteoporosis-drugs
    -market-4018

18
About Us
  • Coherent Market Insights is a global market
    intelligence and consulting organization focused
    on assisting our plethora of clients achieve
    transformational growth by helping them make
    critical business decisions.
  • What we provide
  • Customized Market Research Services
  • Industry Analysis Services
  • Business Consulting Services
  • Market Intelligence Services
  • Long term Engagement Model
  • Country Specific Analysis

19
Contact Us
  • Mr. Shah
  • Coherent Market Insights Pvt.Ltd.
  • Address 1001 4th Ave, 3200 Seattle, WA 98154,
    U.S.
  • Phone 1-206-701-6702
  • Email sales_at_coherentmarketinsights.com

20
  • Thank You!
  • Kindly follow CMI Social Media
    Profiles for the latest company updates
  • Facebook
  • Linkedin
  • Twitter
  • https//www.coherentmarketinsights.com/
About PowerShow.com